Young MS Researchers Invited to Apply for Marilyn Hilton Award
The Conrad N. Hilton Foundation announced that nominations are now being accepted for the Marilyn Hilton Award for Innovation in Multiple…
Articles by Patricia Silva, PhD
MS, Spinal Injuries Highlighted at Paralyzed Veterans of America Summit
Paralyzed Veterans of America recently held its annual health conference, called 2016 Summit + EXPO, focused on the latest research…
900 Cyclists Raise Nearly $1.2M for Multiple Sclerosis in Quebec Fundraiser
More than 900 people biked through the Mauricie region of Quebec, Canada, late last month, raising money for the Quebec Division of…
RegeneRx to Receive EU Patent for Molecule That May Lead to MS Remyelination Therapy
RegeneRx Biopharmaceuticals announced that it has received an Intent to Grant notice from the European Patent Office (EPO) regarding a patent…
TG Therapeutics’ Potential Neuromyelitis Optica Treatment Named Orphan Drug by FDA
The U.S. Food and Drug Administration (FDA) has designated TG-1101 (ublituximab), a glycoengineered anti-CD20 monoclonal antibody by TG Therapeutics, an orphan drug to…
Lemtrada to Treat Relapsing MS Now Part of New Brunswick, Canada, Drug Program
The Government of New Brunswick added Lemtrada (alemtuzumab), by Sanofi Genzyme, to the New Brunswick Prescription Drug Program (NBPDP) through special…
900 Cyclists to Raise Money for MS in Biking Event in Quebec This Weekend
The Quebec Division of the Multiple Sclerosis Society of Canada (MSSC) announced that this year’s 27th Medavie Blue Cross…
Can Diet Ease MS Fatigue? Clinical Trial, Now Recruiting, Wants to Find Out
The National Multiple Sclerosis Society announced that it has dedicated more than $1 million to support a clinical study at the University…
Teva’s New Copaxone Formulation for RRMS Approved by Health Canada
Health Canada has approved Teva Canada Innovation‘s three-time weekly 40 mg/mL injection of Copaxone (glatiramer acetate) that allows less…
Video Series Helps to Guide MS Patients in US with Legal and Planning Issues
A new video series for multiple sclerosis patients in the U.S. looks to help them better understand the complex legal…
Feldenkrais: Awareness of Movement for Those with MS
In a fair world, reading books would burn the most calories, eating ice cream would be chock-full of antioxidants and…
A&W Hosts ‘Burgers to Beat MS’ Fundraiser on Aug. 25 Across Canada
A&W Food Services of Canada is celebrating its “Burgers to Beat MS” day on Thursday, Aug. 25, and for an 8th year will…
Blood Test Seen to Distinguish MS from Other Neurological Conditions
Researchers at Michigan State University suggest that a blood test can distinguish patients with multiple sclerosis (MS) from people…
What to Ask Before Participating in a Multiple Sclerosis Clinical Trial
There are several key questions that a participant will want answered before enrolling in a clinical trial. Many are listed here, but patients should feel free…
Specific Definition of Fatigue in MS Proposed as Way to Advance Research into Symptom
Researchers from Colorado State University propose a new model of fatigue in multiple sclerosis (MS), designed to overcome the…
Zinbryta, a Relapsing MS Therapy, Now Available at Diplomat Pharmacy in US
Diplomat Pharmacy, the largest independent specialty pharmacy in the U.S., is now dispensing the limited-distribution drug Zinbryta (daclizumab) as a…
MSAA Opens New Online Community Forum for MS Patients, Caregivers
The Multiple Sclerosis Association of America (MSAA) recently announced the official launch of My MSAA Community, a free online…
New Pre-HSCT Treatment May Make Stem Cell Transplants a Safer Option for MS Patients
Scientists at Stanford University School of Medicine have developed a method for stem cell transplants that may do away with…
Treating MS Soon After Symptoms Appear Can Delay Relapses, Study Says
A long-term study underscores the potential benefits, especially in terms of relapses, of multiple sclerosis (MS) patients beginning treatment as soon as possible…
Early Disease Activity in MS Seen to Have Little Long-Term, Prognostic Value
A large study of multiple sclerosis patients (MS) came to the conclusion that clinical and brain imaging assessments drawn from…
Brain Inflammation Countered by Neuronal Growth in Mouse Model of MS
As inflammation and neuronal death progressed in the brains of mice with multiple sclerosis (MS), a molecular signaling pathway with…
PCORI Awards $2 Million to Study Treatments for Fatigue in MS Patients
The Patient-Centered Outcomes Research Institute (PCORI) recently awarded a sum of $5.5 million to two researchers at the University…
ACTRIMS Forum 2017 with Latest MS Research Set for February in Orlando
The Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) recently announced that its second annual ACTRIMS…
MS Foundation Asks Public to Help Grant 30 More Wishes for Its 30th Anniversary
The Multiple Sclerosis (MS) Foundation wants to mark its 30th anniversary by granting 30 more wishes to MS patients in need…
Gilenya Seen as Most Effective in Younger and Previously Untreated Patients with Relapsing MS
A study analyzing results from three Phase 3 clinical trials shows that Gilenya (fingolimod) effectively prevents relapses in different types…
Phase 3 Study of Ocrevus in Relapsing MS Patients Now Recruiting in US and Canada
A Phase 3 clinical trial exploring Ocrevus (ocrelizumab) in patients with relapsing-remitting multiple sclerosis (RRMS) is now recruiting participants. The…
PCORI Awards $20M to 4 Studies Comparing Current Drug and Rehab Therapies for MS
The National Multiple Sclerosis Society reported that the Patient-Centered Outcomes Research Institute (PCORI) has granted nearly $20 million…
Queen’s University Belfast Awarded £2M in Bid to Reverse Myelin Damage in MS
Researchers at Queen’s University Belfast are studying how myelin might be repaired, in an attempt to reverse the damage caused by…
Gut Bacteria and Multiple Sclerosis: What We Already Know, and What We’ve Still to Learn
Gut bacteria and health have been topics of considerable scientific speculation in recent years, and the field of multiple sclerosis (MS)…
Ontario Adds Lemtrada, a Relapsing MS Therapy, to Its Drug Coverage Program
Sanofi Genzyme announced that the Government of Ontario has added Lemtrada (alemtuzumab) to the province’s Exceptional Access Program (EAP),…